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Background: Due to economic constraints, cancer therapies are under close scrutiny by clinicians, pharmacists and
payers alike. There is no published pharmacoeconomic evidence guiding the choice of first-line therapy for
advanced renal cell carcinoma (RCC) in the Spanish setting. We aimed to develop a model describing the natural
history of RCC that can be used in healthcare decision-making. We particularly analyzed the budget impact
associated with the introduction of pazopanib compared to sunitinib under the Spanish National Healthcare System
(NHS) perspective.
Methods: We developed a Markov model to estimate the future number of cases of advanced RCC (patients with
favorable or intermediate risk) resulting either from initial diagnosis or disease progression after surgery. The model
parameters were obtained from the literature. We assumed that patients would receive either pazopanib or
sunitinib as first-line therapy until disease progression. Pharmacological costs and costs associated with the
management of adverse events (AE) were considered. A univariate sensitivity analysis was undertaken in order to
test the robustness of the results.
Results: The model predicted an adult RCC prevalence of 7.5/100,000 (1-year), 20.7/100,000 (3-year) and 32.5/
100,000 (5-year). These figures are very close to GLOBOCAN reported RCC prevalence estimates of 7.6/100,000, 20.2/
100,000 and 31.1/100,000, respectively. The model predicts 1,591 advanced RCC patients with favorable or
intermediate risk in Spain in 2013. Annual per patient pharmacological costs were €32,365 and €39,232 with
pazopanib and sunitinib, respectively. Annual costs associated with the management of AE were €662 and €974,
respectively. Overall annual per patient costs were €7,179 (18%) lower with pazopanib compared to sunitinib. For
every point increase in the percentage of patients treated with pazopanib, the NHS would save €67,236. If all the
1,591 patients predicted were treated with pazopanib, the NHS would save €6,723,622 in 2013. Results were robust
according to the sensitivity analysis.
Conclusions: We developed a model that accurately reproduces the natural history of RCC and can be thus used
in healthcare decision-making. When applied to the Spanish case, the introduction of pazopanib results in savings
for the NHS, as a consequence of both reduced pharmacological costs and lower costs associated with the
management of AE compared to sunitinib.
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Renal cell carcinoma (RCC) is the most common kid-
ney cancer [1] and accounts for approximately 3% of
all cancers in males and 2% in females [2]. Advanced
RCC has traditionally been a difficult to treat disease
due to its inherent resistance to cytotoxic therapy, ra-
diation or hormone therapy [3]. Prior to the advent
of angiogenesis inhibitors, interferon alfa (INF-α) and
interleukin-2 (IL-2) were the main therapies used for
the treatment of advanced RCC, despite the signifi-
cant toxicity and limited efficacy associated with their
use [4,5].
Advances in the understanding of the molecular
pathways of the tumor biology have enabled the identi-
fication of specific molecular targets for therapy, in-
cluding the vascular endothelial growth factor (VEGF),
platelet-derived growth factor (PDGF) and mammalian
target of rapamycin (mTOR), what has led to the devel-
opment of several drugs (sorafenib [6], sunitinib [7],
bevacizumab (plus IFN-α) [8,9], temsirolimus [10] and
everolimus [11]) that have substantially improved
outcomes for RCC patients [12]. Pazopanib, a novel
tirosinkinase inhibitor that targets VEGF, PDGF and
stem cell factor receptor (c-Kit), is the latest drug ap-
proved for first line treatment of advanced RCC [13].
Pazopanib, sunitinib and bevacizumab (plus IFN-α) are
recommended in the clinical guidelines for first-line
treatment of advanced RCC in patients with favorable
and intermediate risk [14-16].
COMPARZ (COMParing the efficacy, sAfety and toleR-
ability of paZopanib vs. sunitinib) phase III clinical trial
has evaluated the efficacy and safety of pazopanib com-
pared to sunitinib in subjects with advanced RCC who
had received no prior systemic therapy for advanced RCC.
Pazopanib demonstrated non-inferiority to sunitinib in
terms of median progression-free survival (PFS): 8.4 (95%
CI: 8.3; 10.9) and 9.5 (95% CI: 8.3; 11.1) months, respect-
ively (HR = 1.05 (95% CI: 0.90; 1.22 < 1.25)) [17].
Despite the current economic environment in which
healthcare resources are scarce, to our knowledge, there
is no published pharmacoeconomic evidence guiding
the choice of one therapy over another as first-line ther-
apy for advanced RCC in the Spanish setting. We aimed
to develop a population-based model that describes the
natural history of RCC and predicts the number of
future cases of advanced RCC, so that it can be used in
healthcare decision-making. We further aimed to use
this model to analyze the budget impact (i.e. the
financial consequence of adopting a new healthcare
intervention [18]) associated with the introduction of
pazopanib, compared to the current standard of care in
Spain (i.e. sunitinib), in first-line treatment of advanced
RCC under the Spanish National Healthcare System
(NHS) perspective.Methods
Epidemiology of advanced RCC in Spain
We modeled the annual number of patients diagnosed
with or progressing to advanced RCC in Spain by means
of a Markov model. Markov models are useful to repre-
sent random processes which evolve over time. With
this methodology, a specific disease is described as a
chain of different health states, and movements between
those states over discrete time periods (cycles) occur
with a given probability (transition probability). By run-
ning the model over a sufficient number of cycles, the
long-term outcomes of the disease are obtained [19].
In this particular case, 13 health states were defined:
GP40+: general population aged 40 and above; RCC1 to
RCC10: 10-year cohort of RCC prevalence; ARCC: ad-
vanced RCC patients; and PARCC/D: post-advanced
RCC patients or death (Figure 1). Since the probability
of progression to advanced RCC after surgery for local-
ized disease depends on time after the intervention [20],
we used tunnel states (RCC1 to RCC10) to incorporate
this disease feature into the model. Tunnel states can be
visited only in a fixed sequence. Their purpose is to
apply to transition probabilities a temporary adjustment
that lasts more than one cycle [21], thus overcoming the
so-called “lack of memory” limitation of Markov chains.
In order to allow patients with disease progression after
surgery to be incorporated into the advanced RCC co-
hort, we carried out a simulation of the progression of
RCC in the period 2003-2015, considering annual cycles.
After 10 years, we assumed that patients treated for lo-
calized RCC were free of disease.
Model parameters were obtained from GLOBOCAN
incidence figures, demographic data from the Spanish Na-
tional Institute of Statistics and other evidence from the
existing literature. Model parameters and their supporting
references are presented in Table 1 [7,13,20,22-26].
Cost analysis
We considered the annual pharmacological costs and
also the costs associated with the management of ad-
verse events (AE) for both pazopanib and sunitinib.
Other costs, such as follow-up costs, were assumed
to be equal for both treatments and thus were not
taken into account. All costs were expressed in con-
stant January 2013 Euro (€).
We considered 8 cycles of a 6-week treatment with ei-
ther pazopanib (400 mg twice daily without interruption)
or sunitinib (50 mg once daily for 4 weeks followed by a
2-week rest) per year. Ex-factory prices (VAT included)
for pazopanib and sunitinib were obtained from the
Spanish Council of Pharmacists database [27]. Patients
who progressed on either pazopanib or sunitinib dis-
continued treatment. Based on progression-free survival
Kaplan-Meier curves reported in COMPARZ [17], we
Figure 1 Markov model diagram. Detailed legend: GP40+: general population aged 40 and above, RCC1 to RCC10: 10-year cohort of RCC
prevalence, ARCC: advanced RCC patients, PARCC/D: post-advanced RCC patients or death.
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with pazopanib or sunitinib 57% of the time within a year.
Incidence of AE for both pazopanib and sunitinib was
obtained from COMPARZ [17]. In this analysis, we fo-
cused on AE with reported incidences (all grades) greater
than or equal to 30% in either arm. Non-specific AE or
those thought not to have contributed significantly to theTable 1 Model parameters values and references: base case a
Base case
Parameter
Kidney cancer incidence 40+ (per 100,000) 19.8
RCC incidence (over kidney cancer incidence) 90%
RCC incidence at diagnosis (over RCC incidence) 20%
RCC mortality (localized disease) 1.66%
Transition to advanced RCC (year 1) 13.18%
Transition to advanced RCC (years 2 and 3) 4.57%
Transition to advanced RCC (years 4 and 5) 1.92%
Transition to advanced RCC (year 6 and 7) 1.64%
Transition to advanced RCC (year 8 to 10) 1.26%
Advanced RCC of favorable or intermediate risk 89%
Transition to post-advanced RCC 100%overall costs (e.g. changes in hair color or taste alteration)
were not taken into account. Laboratory abnormalities not
associated with pharmacological treatment (e.g. creatinine
increase or hypophosphatemia) were not considered. AE
reported for pazopanib and sunitinib in COMPARZ are
referred to median drug exposures of 8.4 months and
9.5 months, respectively. We assumed that reported ratesnd sensitivity analysis
Sensitivity analysis References
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purposes of this analysis. Unit costs associated with AE
management in the Spanish setting were taken from the
literature [28,29] and expert judgment.Budget impact analysis
Budget impact analyses (BIA) are used to estimate the
financial consequences of adoption of new healthcare in-
terventions within a specific healthcare setting. A new
healthcare intervention can either introduce savings into
a healthcare system or put additional pressure on the
healthcare budget due to modifications in the total
population affected by a disease (e.g. better diagnostic
tools), in the future population (e.g. preventive interven-
tions that reduce disease incidence) or in the healthcare
resources or drugs used to manage the disease [18].
We combined the estimated number of patients with
advanced RCC provided by the Markov model and the
cost analysis described above to simulate the budget
impact resulting from the introduction of pazopanib,
compared to sunitinib, under the Spanish NHS perspec-
tive. A temporal horizon of 3 years (2013–2015) was
considered. Incremental annual costs were computed
for any percentage of patients treated with pazopanib

















Figure 2 RCC adult prevalence (cases per 100,000), Spain 2013.Sensitivity analysis
In order to test the robustness of the model, a univariate
sensitivity analysis was undertaken. In this sensitivity
analysis, one parameter is changed at a time and the
new incremental cost is calculated. The lower and upper
values of the model parameters used for this analysis are
presented in Table 1.
Results
Adult RCC prevalence predicted by the model is as
follows: 7.5/100,000 (1-year); 20.7/100,000 (3-year) and
32.5/100,000 (5-year). As can be seen in Figure 2, the
model accurately matches GLOBOCAN reported preva-
lence figures for RCC (90% of kidney cancer prevalence
[24]): 7.6/100,000, 20.2/100.000 and 31.1/100,000, re-
spectively. These results validate the model externally in
terms of its structure and the parameters chosen. The
model predicts a total of 1,591 advanced RCC patients
with favorable or intermediate risk in Spain in 2013.
This figure is the result of the sum of the incident pa-
tients diagnosed with advanced disease within a year and
those patients who relapse after surgery for the treat-
ment of localized disease.
Pharmacological costs per cycle for pazopanib and
sunitinib were €4,046 and €4,904, respectively (Table 2).
Annual (8 cycles) per patient pharmacological costs were





Table 2 Epidemiologic and economic results
Patients Pazopanib Sunitinib Difference Percent
Per patient and cycle pharmacological costs €4,046 €4,904 -€858 −17.50%
Per patient annual (8 cycles) pharmacological costs €32,365 €39,232 -€6,867 −17.50%
Per patient annual costs associated with AE management €662 €974 -€312 −32.03%
Per patient overall annual costs €33,027 €40,206 -€7,179 −17.85%
Year 2013
Advanced RCC at diagnosis 854
Progressions to advanced RCC 934
Advanced RCC (favorable or intermediate risk) 1,591
Pharmacological costs €29,350,968 €35,578,198 -€6,227,230 −17.50%
Overall costs €30,404,210 €37,127,832 -€6,723,622 −18.11%
Year 2014
Advanced RCC at diagnosis 866
Progressions to advanced RCC 948
Advanced RCC (favorable or intermediate risk) 1,615
Pharmacological costs €28,925,945 €35,063,000 -€6,137,056 −17.50%
Overall costs €29,963,935 €36,590,195 -€6,626,260 −18.11%
Year 2015
Advanced RCC at diagnosis 878
Progressions to advanced RCC 962
Advanced RCC (favorable or intermediate risk) 1,638
Pharmacological costs €28,483,391 €34,526,553 -€6,043,162 −17.50%
Overall costs €29,505,501 €36,030,382 -€6,524,881 −18.11%
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(Table 3). The overall annual per patient cost for
pazopanib was €7,179 (18%) lower compared to sunitinib.
The budget impact resulting from the introduction of
pazopanib as a function of the percentage of patients
treated is depicted in Figure 3. In 2013, a point increase in
the percentage of patients treated with pazopanib com-
pared to sunitinib would prevent the NHS from incurring
an overall annual amount of €67,236. In the most efficient
scenario, where all the 1,591 advanced RCC patients
predicted by the model receive pazopanib, we estimate po-
tential annual savings for the NHS of €6,723,622. Results
for 2014 and 2015 are also presented in Table 2.
The univariate sensitivity analysis confirmed the ro-
bustness of the model. Among the model parameters,
kidney cancer incidence, the proportion of advanced
RCC patients with favorable or intermediate risk, the
percentage of advanced RCC at diagnosis and RCC inci-
dence were the most relevant. The incremental cost
remained negative for any scenario considered, meaning
that the introduction of pazopanib results in savings for
the NHS (Figure 4).
Discussion
Healthcare expenditure has drawn the attention of
payers as well as of clinicians involved in oncologic caredue to both the increased pressure on healthcare bud-
gets as a consequence of the current economic environ-
ment and the relentless increase in healthcare spending
as a portion of countries’ Gross Domestic Product over
the past decades [30]. Anti-VEGF therapies for RCC are
not an exemption and are subject to scrutiny from
healthcare budget holders, pharmacists and oncologists
alike. In this context, we sought to develop a model that
describes the natural history of RCC, so that it can be
applied to healthcare decision-making. To our knowledge,
there are no published estimates of the future number of
cases of advanced RCC in our country. We thus developed
a time-dependent population-based Markov model to pre-
dict the future cases of advanced RCC and used this
model to examine the budget impact associated with the
introduction of pazopanib, compared to sunitinib, in the
treatment of first-line advanced RCC patients with favor-
able or intermediate risk.
In order to effectively capture all the relevant costs
and consequences, guidelines recommend BIA popula-
tions to be open [18,31], in the sense that individuals can
enter or leave the population pool depending on whether
they meet the criteria for inclusion (i.e. diagnosis of ad-
vanced RCC). This is in contrast with most Markov
models in which populations are closed, with hypothetical
patient cohorts being followed throughout a defined time
Table 3 Costs associated with the management of adverse events
Unit cost Pazopanib Sunitinib Cost difference
Adverse event Value Reference Incidence Per patient cost Incidence Per patient cost
Anorexia [28] €4.97 €4.97 €0.00
Grades I and II €13.43 36% 34%
Grade III €13.43 1% 3%
Diarrhea [28] €127.12 €161.01 -€33.89
Grades I and II €6.05 54% 49%
Grade III €1,376.13 9% 7%
Grade IV €6,171.42 1%
Fatigue [28] €0.89 €1.02 -€0.13
Grades I and II €1.62 44% 45%
Grade III €1.62 10% 17%
Grade IV €1.62 1% 1%
Hand-foot syndrome [29] €23.30 €52.20 -€28.90
Grades I and II €51.87 23% 38%
Grade III €189.41 6% 11%
Grade IV €1,165.50 1%
Hypertension Expert judgment €33.72 €32.88 €0.84
Grades I and II €16.88 30% 25%
Grade III €16.88 15% 15%
Grade IV €2,612.71 1% 1%
Nausea [28] €52.28 €52.59 -€0.31
Grades I and II €31.24 43% 44%
Grade III €1,942.30 2% 2%
Laboratory abnormality
Anemia [28] €65.77 €126.91 -€61.14
Grades I and II €200.26 29% 53%
Grade III €261.70 1% 6%
Grade IV €507.46 1% 1%
ALT Expert judgment €136.70 €79.77 €56.93
Grades I and II €119.30 43% 38%
Grade III €236.16 15% 4%
Grade IV €2,498.64 2% 1%
Neutropenia [28] €138.00 €248.60 -€110.60
Grades I and II €356.78 32% 48%
Grade III €356.78 4% 19%
Grade IV €955.53 1% 1%
Trombocitopenia [28] €78.83 €214.13 -€135.30
Grades I and II €139.29 37% 56%
Grade III €449.54 3% 18%
Grade IV €1,380.29 1% 4%
Total €661.58 €974.08 -€312.50
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the changes in the advanced RCC population by means of
a time-dependent population-based Markov model, based
on the incidence of advanced RCC at diagnosis and on the
likelihood of disease recurrence after surgery for localized
disease. Patients leave the model when they experienceprogression during first-line therapy for advanced disease.
Markov models have been used in other disease areas as
well for this purpose [32].
The model accurately matches GLOBOCAN reported
prevalence figures for RCC in Spain, providing evidence








































































































Pazopanib's pre-introduction scenario Pazopanib's post-introduction scenario Incremental cost









- 8,000 - 7,000 - 6,000 - 5,000 - 4,000 - 3,000 - 2,000 - 1,000 0
Kidney cancer incidence 40+ (per 100,000) = 17.82
Kidney cancer incidence 40+ (per 100,000) = 21.78
Advanced CCR (favorable or intermediate risk) = 80.10%
Advanced CCR (favorable or intermediate risk) = 97.90%
Proportion of advanced CCR incidence at diagnosis = 15%
Proportion of advanced CCR incidence at diagnosis = 25%
Proportion of CCR incidence = 85%
Proportion of CCR incidence = 95%
In thousand €
Figure 4 Sensitivity analysis: incremental cost resulting from univariate parameter changes (Tornado).
Villa and Hernández-Pastor BMC Cancer 2013, 13:399 Page 7 of 9
http://www.biomedcentral.com/1471-2407/13/399
Villa and Hernández-Pastor BMC Cancer 2013, 13:399 Page 8 of 9
http://www.biomedcentral.com/1471-2407/13/399disease and that it is therefore a reliable tool for estimat-
ing the future prevalence of advanced RCC based on
RCC incidence. Moreover, the model results are robust
as demonstrated by the sensitivity analysis performed.
Even though this model includes Spanish-specific pa-
rameters (e.g. incidence rates and baseline populations),
disease-specific parameters, such as the percentage of
patients with advanced disease at diagnosis and the
time-dependent probabilities of recurrence, have been
obtained from the best available sources in the literature
and are not country-specific. This model can be there-
fore easily transferred to other settings by simply re-
placing Spanish population estimates (publicly available
from national statistics) and renal cancer incidence
figures (publicly available from GLOBOCAN [22]) by
country-specific data.
In our study, pazopanib results in considerable savings
for the Spanish NHS, as a consequence of both reduced
pharmacological costs and lower costs associated with
the management of AE. Based on COMPARZ results,
there are some AE that occur with a higher frequency
with sunitinib (e.g. thrombocytopenia, anemia and neu-
tropenia), while others seem to be more frequent with
pazopanib (e.g. liver enzyme elevation) [17]. We thus
included the costs associated with the management of
AE for both drugs in order to account for such differ-
ences. Despite being very relevant for RCC patients
[33], fatigue and hand-foot syndrome are not associated
with a great increase in healthcare resource use or
costly concomitant medications. They thus had a lim-
ited contribution to the difference in overall therapy
costs in our analysis.Conclusions
We developed a time-dependent population-based Mar-
kov model that can be used to estimate the future num-
ber of cases of advanced RCC. We used it to undertake
the BIA resulting from the introduction of pazopanib
compared to sunitinib in the treatment of first-line ad-
vanced RCC under the Spanish NHS perspective. The
introduction of pazopanib is cost-saving for the Spanish
NHS, as a consequence of both reduced pharmacological
costs and lower costs associated with the management
of AE.Abbreviations
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